As of Friday close, Pacific Biosciences of California Inc.’s (NASDAQ:PACB) stock was down -$0.06, moving down -0.67 percent to $8.94. The average number of shares traded per day over the past five days has been 4,348,500 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.48 fall in that time frame. In the last twenty days, the average volume was 3,673,235, while in the previous 50 days, it was 3,683,346.
Since last month, PACB stock retreated -14.78%. Shares of the company fell to $8.88 on 09/22/23, the lowest level in the past month. A 52-week high of $14.55 was reached on 07/18/23 after having rallying from a 52-week low of $4.97. Since the beginning of this year, PACB’s stock price has risen by 9.29% or $0.76, and marked a new high 19 times. However, the stock has declined by -38.56% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
PACB stock investors should be aware that Pacific Biosciences of California Inc. (PACB) stock had its last reported insider trading activity 5 days ago on Sep 18. HENRY CHRISTIAN O, the of the company, disposed of 96,844 shares for $10.12 on Sep 18. It resulted in a $980,255 divestment by the insider. HENRY CHRISTIAN O sold 10,000 shares at an average price of $10.45 on Sep 11. The insider now owns 1,202,939 shares following the transaction. On Aug 17, Eidel Jeff sold 25,936 shares at $10.60 apiece. The transaction was valued at $274,844.
Valuation Metrics
The stock’s beta is 1.69. Besides these, the trailing price-to-sales (P/S) ratio of 16.20, the price-to-book (PB) ratio of 3.48.
Financial Health
In the recent quarter, Pacific Biosciences of California Inc.’s quick ratio stood at 3.20, while its current ratio was 3.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 1.39, and the total debt-to-equity ratio was 1.39. On the profitability front, the trailing twelve-month gross margin is 32.60% percent. Based on annual data, PACB earned $49.03 million in gross profit and brought in $128.3 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -21.00%. Return on equity (ROE) for the past 12 months was -50.60%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PACB’s revenue rose 25.4% to $38.9 million during the quarter, while net income inched up to $47.55 million. During the quarter, the company generated -$72.11 million in EBITDA. The liabilities of Pacific Biosciences of California Inc. were 1.21 billion at the end of its most recent quarter, and its total debt was $939.06 million. The value of shareholders’ equity is $250.56 million.
Technical Picture
This quick technical analysis looks at Pacific Biosciences of California Inc.’s (PACB) price momentum. With a historical volatility rate of 76.30%, the RSI 9-day stood at 27.58% on 22 September.
With respect to its five-day moving average, the current Pacific Biosciences of California Inc. price is down by -14.20% percent or -$1.48. At present, PACB shares trade -11.13% below its 20-day simple moving average and -20.95% percent below its 100-day simple moving average. However, the stock is currently trading approximately -35.59% below its SMA50 and -10.87% below its SMA200.
Stochastic coefficient K was 4.59% and Stochastic coefficient D was 6.57%, while ATR was 0.57. Given the Stochastic reading of 1.95% for the 14-day period, the RSI (14) reading has been calculated as 31.73%. As of today, the MACD Oscillator reading stands at -0.92, while the 14-day reading stands at -1.18.
Analyst Ratings
Pacific Biosciences of California Inc. (PACB) has been rated Overweight by analysts. According to 0 brokerage firms, PACB is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Pacific Biosciences of California Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $15.00, the current consensus forecast for the stock is $13.00 – $19.00. Based on these forecasts, analysts predict Pacific Biosciences of California Inc. (PACB) will achieve an average price target of $15.18.
